Data in prostate cancer has shown SNHG1 is regulated by dihydrotestosterone treatment, and there is a correlation between high SNHG1 expression and pathological stage, Gleason score, and time to biochemical recurrence [6]. This evidence concerns the gene SNHG1 and prostate cancer.